Please assess the completion status of the following clinical trial:

Trial Title: Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients or their legal guardians who provide written informed consent to participate in the study on a voluntary basis. For adolescent patients, informed consent/assent of voluntary participation should be obtained in accordance with local requirements.~2. Male or female patients ≥ 12 years at the time of signing the informed consent/assent form.~3. Patients with a diagnosis of influenza confirmed by all of the following:~   1. Fever ≥ 38ºC (axillary) during the predose examinations or within the 4 hours prior if antipyretics were taken~  2. A positive rapid influenza diagnostic test (RIDT) result OR A patient with a negative RIDT may be enrolled if the patient reports contact with a known case of influenza within the prior 7 days and all other inclusion criteria are met.~  3. At least 1 each of the following general and respiratory symptoms associated with influenza is present with a severity of moderate or greater:~   i. General symptoms (headache, feverishness or chills, muscle or joint pain, or fatigue) ii. Respiratory symptoms (cough, sore throat, or nasal congestion)~4. The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either:~   1. Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)~  2. Time when the patient experiences at least 1 new general or respiratory symptom~5. If a women of childbearing potential, agrees to use a highly effective method of contraception for 3 months after the first dose of study drug~6. Patients will be considered at high risk\* of influenza complications due to the presence of at least 1 of the following inclusion criteria:~   1. Asthma or chronic lung disease (such as chronic obstructive pulmonary disease or cystic fibrosis)~  2. Endocrine disorders (including diabetes mellitus)~  3. Residents of long-term care facilities (eg, nursing homes)~  4. Compromised immune system (including patients receiving corticosteroids not exceeding 20 mg of prednisolone or equivalent, and patients being treated for human immunodeficiency virus \[HIV\] infection with a CD4 count \> 350 cells/mm³ within the last 6 months)~  5. Neurological and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy \[seizure disorders\], stroke, muscular dystrophy, or spinal cord injury)~  6. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease), excluding hypertension without any other heart-related symptoms~  7. Adults aged ≥ 65 years~  8. American Indians and Alaskan Natives~  9. Blood disorders (such as sickle cell disease)~  10. Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders)~  11. Morbid obesity (body mass index ≥ 40 kg/m²)~  12. Women who are within 2 weeks postpartum and are not breastfeeding~Exclusion Criteria:~1. Patients with severe influenza virus infection requiring inpatient treatment.~2. Patients with known allergy to oseltamivir (Tamiflu®).~3. Patients unable to swallow tablets or capsules.~4. Patients who have previously received baloxavir marboxil.~5. Patients weighing ≤ 40 kg.~6. Patients who have been exposed to an investigational drug within 30 days prior to the predose examinations.~7. Women who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test at the predose examinations:~   1. Postmenopausal women (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test)~  2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation~8. Patients with concurrent infections at the predose examinations requiring systemic antimicrobial therapy.~9. Patients with liver disease associated with hepatic impairment.~10. Patients with cancer within the last 5 years (unless nonmelanoma skin cancer).~11. Patients with untreated HIV infection or treated HIV infection with a CD4 count below 350 cells/mm3 in the last 6 months.~12. Patients with immunosuppression following organ or bone marrow transplants.~13. Patients exceeding 20 mg of prednisolone or equivalent dose of chronic systemic corticosteroids.~14. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir or amantadine within 30 days prior to the predose examinations.~15. Patients who have received an investigational monoclonal antibody for a viral disease in the last year.~16. Patients with known creatinine clearance ≤ 60 mL/min.~17. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Baloxavir Marboxil (Type: EXPERIMENTAL): Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of \< 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
- Oseltamivir (Type: ACTIVE_COMPARATOR): Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.

Based on this trial design, predict the completion outcome and termination type (if applicable).